Cymabay Therapeutics, Inc. (CBAY) Hit 52-Week High

January 20, 2018 - By Adrian Mccoy

The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) hit a new 52-week high and has $10.71 target or 5.00 % above today’s $10.20 share price. The 7 months bullish chart indicates low risk for the $447.41M company. The 1-year high was reported on Jan, 20 by Barchart.com. If the $10.71 price target is reached, the company will be worth $22.37 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.59% or $0.06 during the last trading session, reaching $10.2. About 612,884 shares traded or 1.95% up from the average. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since January 20, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 earnings per share, up 56.67 % or $0.17 from last year’s $-0.3 per share. After $-0.21 actual earnings per share reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 17 analyst reports since July 21, 2015 according to SRatingsIntel. Piper Jaffray initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, July 21. Piper Jaffray has “Overweight” rating and $4 target. Oppenheimer maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, January 10 with “Buy” rating. The stock has “Neutral” rating by H.C. Wainwright on Wednesday, January 4. The stock has “Buy” rating by Leerink Swann on Tuesday, November 28. Piper Jaffray maintained the stock with “Buy” rating in Monday, September 11 report. The firm earned “Buy” rating on Monday, July 17 by H.C. Wainwright. The company was initiated on Friday, July 1 by Roth Capital. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright on Wednesday, March 30. The company was maintained on Monday, July 17 by Piper Jaffray. The rating was initiated by Cantor Fitzgerald with “Buy” on Tuesday, September 19.

More news for Cymabay Therapeutics, Inc. (NASDAQ:CBAY) were recently published by: Marketwatch.com, which released: “CymaBay Therapeutics Inc.” on July 20, 2014. Streetinsider.com‘s article titled: “CymaBay Therapeutics (CBAY) Enters Exclusive Licensing Deal with Kowa …” and published on January 03, 2017 is yet another important article.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $447.41 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.